Safety of Drug-Eluting Beads Chemoembolization in Patients with Pre-Exisiting Transjugular Intrahepatic Portosystemic Shunt
dc.contributor.other | Pirasteh, Ali | en |
dc.contributor.other | Shenoy-Bhangle, Anu | en |
dc.contributor.other | Ganguli, Shoey | en |
dc.contributor.other | Kalva, Sanjeeva | en |
dc.creator | Rief, Katherine M. | en |
dc.date.accessioned | 2015-02-18T15:06:58Z | |
dc.date.available | 2015-02-18T15:06:58Z | |
dc.date.issued | 2015-01-26 | |
dc.description | The 53rd Annual Medical Student Research Forum at UT Southwestern Medical Center (Monday, January 26, 2015, 2-5 p.m., D1.602) | en |
dc.description.abstract | STUDY AIM: To assess the safety of transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC) in patients with a pre-existing transjugular intrahepatic portosystemic shunt (TIPS). METHODS: A multi-institutional, IRB approved, retrospective review was conducted of patients with a pre-existing patent TIPS who underwent TACE to treat unresectable HCC between 2009 and 2014. Patients (7 male, 4 female) ranging from 39 to 74 years of age (mean 61, SD 11) were included. Parameters of interest included type of TACE (drug-eluting beads or traditional), number of TACE procedures, 30-day mortality from last TACE procedure, and any complications or toxicity following TACE. RESULTS:Ten of the eleven patients underwent super-selective drug-eluting bead TACE, using doxorubicin at a dosage ranging from 50mg to 150mg (Median 100mg). Number of TACE procedures per patient ranged from 1 to 4 (Median 1). Three of the patients (3/11, 27%) experienced toxicity (CTAE v4) grade 2 or higher immediately following the TACE procedure. Two of these patients experienced Grade 2 Albumin Toxicity. Another had Grade 3 Toxicity of AST, ALT and bilirubin. 73% of patients were discharged within 24 hours. The remaining 3 patients were hospitalized for pain, edema, or acute pancreatitis for 3, 5 and 20 days respectively. All eleven patients were alive and discharged from the hospital 30 days after the most recent TACE procedure. DISCUSSION: TACE can be well tolerated by patients with a patent TIPS given adequate liver function. As additional cases are performed we hope to clarify the efficacy and most appropriate TIPS patient population for TACE. | en |
dc.description.sponsorship | Southwestern Medical Foundation | en |
dc.identifier.citation | Rief, K., Pirasteh, A., Shenoy-Bhangle, A., Ganguli, S., & Kalva, S. (2015, January 26). Safety of drug-eluting beads chemoembolization in patients with pre-exisiting transjugular intrahepatic portosystemic shunt. Poster presented at the 53rd Annual Medical Student Research Forum, Dallas, TX. Retrieved from https://hdl.handle.net/2152.5/1539 | en |
dc.identifier.uri | https://hdl.handle.net/2152.5/1539 | |
dc.language.iso | en | en |
dc.relation.ispartofseries | 53rd Annual Medical Student Research Forum | en |
dc.subject | Clinical Research and Case Reports | en |
dc.subject.mesh | Carcinoma, Hepatocellular | en |
dc.subject.mesh | Chemoembolization, Therapeutic | en |
dc.subject.mesh | Liver Neoplasms | en |
dc.subject.mesh | Portasystemic Shunt, Transjugular Intrahepatic | en |
dc.title | Safety of Drug-Eluting Beads Chemoembolization in Patients with Pre-Exisiting Transjugular Intrahepatic Portosystemic Shunt | en |
dc.type | Presentation | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Rief_KM_TIPSTACE_poster_48x36.pdf
- Size:
- 1.11 MB
- Format:
- Adobe Portable Document Format
- Description:
- PDF -- public access
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 297 B
- Format:
- Item-specific license agreed upon to submission
- Description: